Measles-containing-vaccine second-dose (MCV2) immunization coverage in New Zealand
New Zealand: Measles-containing-vaccine second-dose (MCV2) immunization coverage was 88.0% in 2025. ◆ Volatile
Measles-containing-vaccine second-dose (MCV2) immunization coverage in New Zealand, 2000–2025
Source: World Health Organization, Global Health Observatory.
Analysis
In 2025, measles-containing-vaccine second-dose (mcv2) immunization coverage in New Zealand stood at 88.0%.
The figure is up 1.1% on the previous year and up 1.1% over ten years.
Over the whole period, measles-containing-vaccine second-dose (mcv2) immunization coverage in New Zealand peaked at 91.0% in 2020 and was at its lowest, 0.0%, in 2000.
New Zealand ranks 76th of 194 countries on this measure, in the middle of the range.
The series is highly variable year to year, so single readings are best treated with caution.
Measles-containing-vaccine second-dose (MCV2) immunization coverage in New Zealand, year by year
| Year | Value | Change |
|---|---|---|
| 2000 | 0.0% | — |
| 2001 | 0.0% | — |
| 2002 | 0.0% | — |
| 2003 | 0.0% | — |
| 2004 | 0.0% | — |
| 2005 | 0.0% | — |
| 2006 | 0.0% | — |
| 2007 | 0.0% | — |
| 2008 | 0.0% | — |
| 2009 | 0.0% | — |
| 2010 | 0.0% | — |
| 2011 | 86.0% | — |
| 2012 | 85.0% | -1.2% |
| 2013 | 86.0% | +1.2% |
| 2014 | 86.0% | +0.0% |
| 2015 | 87.0% | +1.2% |
| 2016 | 89.0% | +2.3% |
| 2017 | 90.0% | +1.1% |
| 2018 | 90.0% | +0.0% |
| 2019 | 90.0% | +0.0% |
| 2020 | 91.0% | +1.1% |
| 2021 | 82.0% | -9.9% |
| 2022 | 83.0% | +1.2% |
| 2023 | 84.0% | +1.2% |
| 2024 | 87.0% | +3.6% |
| 2025 | 88.0% | +1.1% |
Averages by decade
| Decade | Average | Lowest | Highest | Years |
|---|---|---|---|---|
| 2000s | 0.0% | 0.0% | 0.0% | 10 |
| 2010s | 78.9% | 0.0% | 90.0% | 10 |
| 2020s | 85.8% | 82.0% | 91.0% | 6 |
Countries ranked near New Zealand
More health data for New Zealand
- Un projection of annual infant deaths, annual growth rate -2.94 % change on previous year (2100)
- Heat deaths vs projected death rates, annual growth rate -0.4815 % change on previous year (2090)
- Estimated changes in temperature-related death rates compared to projected death rates 1,116 deaths per 1,000 people (2090)
- Number of infants who die before age 1 33 deaths (2100)
- Population ages 0-14, female, annual growth rate -0.6935 % change on previous year (2025)
- Population ages 0-14, female, per unit of GDP 0 units per US$ of GDP (2025)
- Population ages 0-14, female, per capita 0.087 units per person (2025)
- Population ages 0-14, male, annual growth rate -0.6744 % change on previous year (2025)
- Population ages 0-14, male, per unit of GDP 0 units per US$ of GDP (2025)
- Population ages 0-14, male, per capita 0.0918 units per person (2025)
Frequently asked questions
- What is measles-containing-vaccine second-dose (mcv2) immunization coverage in New Zealand?
- Measles-containing-vaccine second-dose (mcv2) immunization coverage in New Zealand was 88.0% in 2025, according to World Health Organization, Global Health Observatory.
- What is the highest measles-containing-vaccine second-dose (mcv2) immunization coverage recorded in New Zealand?
- The highest recorded value was 91.0% in 2020.
- What is the lowest measles-containing-vaccine second-dose (mcv2) immunization coverage recorded in New Zealand?
- The lowest recorded value was 0.0% in 2000.
- How does New Zealand rank for measles-containing-vaccine second-dose (mcv2) immunization coverage?
- New Zealand ranks 76th out of 194 countries with data for 2025.
- Is measles-containing-vaccine second-dose (mcv2) immunization coverage rising or falling in New Zealand?
- Over the last ten years it is up 1.1%. The long-run trend across the full record is volatile.
- Where does this New Zealand data come from?
- The figures come from World Health Organization, Global Health Observatory, published as part of Measles-containing-vaccine second-dose (MCV2) immunization coverage by the locally recommended age (%) (WUENIC). Statizoid updates them automatically from the source API.
Download this data
CSV · JSON — 26 observations, free to reuse under CC BY-NC-SA 3.0 IGO (WHO).